[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhuhai Trinomab Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100619693","a-phase-4-study-to-evaluate-the-effectiveness-and-safety-of-siltartoxatug-injection-for-tetanus-prophylaxis-following-injury-100619693",false,"NCT07347938","A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury","A Multicenter, Prospective, Non-Randomized, Open-Label, Active-Controlled Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury","Inclusion Criteria:\n\n* Male or female aged ≥18 years.\n* Receiving siltartoxatug for tetanus prophylaxis per its approved labeling, or receiving another passive immunizing agent (human tetanus immunoglobulin \\[HTIG\\], tetanus antitoxin \\[TAT\\], or equine F(ab')₂ fragment \\[F(ab')₂\\]) for tetanus prophylaxis per its labeling.\n* Receiving or planned to receive standard wound management.\n* Providing written informed consent by the subject or their legally authorized representative.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C3 months.\n* Severe cognitive impairment or other condition interfering with the assessment of tetanus development.\n* Currently participating in another interventional clinical trial (observational studies are permitted).","ALL","18 Years",{"count":19,"type":20},6000,"ESTIMATED","OBSERVATIONAL","Study sites were selected from hospitals across diverse regions of China. Approximately 6,000 participants who require passive immunization against tetanus due to various injuries (including those with severe wounds or heavily contaminated injuries) will be enrolled. Per clinical practice:\n\nParticipants receiving siltartoxatug for tetanus prophylaxis and meeting eligibility criteria will be assigned to the siltartoxatug group (n=4,000); Participants receiving other passive immunizing agents (HTIG, TAT, or F(ab')₂) for tetanus prophylaxis and meeting eligibility criteria will be assigned to the control group (n=2,000), comprising approximately 1,000 HTIG recipients and 1,000 TAT\u002FF(ab')₂ recipients. All clinical management decisions, including concomitant tetanus vaccination, will be made by investigators per standard clinical practice at each center.",[24],"Tetanus","NOT_YET_RECRUITING","2026-01-08",{"date":28,"type":29},"2026-01-16","ACTUAL",{"date":31,"type":20},"2026-01-05",{"date":33,"type":20},"2029-03-31",{"name":35,"class":36},"Zhuhai Trinomab Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":47,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":50,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100601241","a-registry-siltartoxatug-injection-for-tetanus-prophylaxis-following-injury-100601241","NCT07107932","A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury","A Large-Sample Real-World Dynamic Cohort Registry: Observing the Clinical Outcomes of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury","Inclusion Criteria:\n\n* 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury;\n* 2\\. Provided signed informed consent by themselves or their legal representatives.\n\nExclusion Criteria:\n\n* None",{"count":46,"type":20},10000,"90 Days","The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.",[24],[51],"Tetanus Prophylaxis","RECRUITING","2026-01-04",{"date":55,"type":29},"2026-01-06",{"date":57,"type":29},"2025-07-31",{"date":59,"type":20},"2029-03-30",{"name":35,"class":36},4,""]